Worldwide Antisense Oligonucleotide Therapeutics Industry to 2030 - Market Trends and Global Forecasts
Share this article Share this article ResearchAndMarkets.coms offering. Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso (duc...
Source: prnewswire.com